Effect of low-dose citrate anticoagulation on the clinical safety and efficacy of direct adsorption of lipoproteins (DALI apheresis) in hypercholesterolemic patients: A prospective controlled clinical trial

Artificial Organs

Volumn 24, Issue 10, 2000, Pages 790-796

  Bosch, T ^a   Heinemann, O ^a   Duhr, C ^a   Wendler, T ^a   Keller, C ^a   Fink, E ^b   Kirschner, T ^c   Klebert, S ^d   Samtleben, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Dialysis Center   (Germany)

^d Fresenius HemoCare Adsorber Technology GmbH   (Germany)

Author keywords

Biocompatibility; Bradykinin; Citrate; DALI; Direct adsorption of lipoproteins; Heparin; Low density lipoprotein apheresis

Indexed keywords

ADSORPTION; BLOOD; LIPOPROTEINS; PATIENT TREATMENT; POLYSACCHARIDES;

ANTI-COAGULATION; BRADYKININ; CITRATE; CLINICAL TRIAL; DIRECT ADSORPTION OF LIPOPROTEIN; LOW DENSITY LIPOPROTEINS; LOW DOSE; LOW-DENSITY LIPOPROTEIN-APHERESIS; PROSPECTIVES;

BIOCOMPATIBILITY;

ANTITHROMBIN; BETA THROMBOGLOBULIN; BRADYKININ; CALCIUM; CHOLESTEROL; CITRIC ACID; COMPLEMENT; ELASTASE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; THROMBIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADSORPTION; ADULT; AGED; ANTICOAGULATION; APHERESIS; ARTICLE; BIOCOMPATIBILITY; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; SAFETY;

EID: 0033759578     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.2000.06647.x     Document Type: Article

References (16)

1. LDL-Hemoperfusion - A new procedure for LDL-apheresis: First clinical application of an LDL-adsorber compatible with human whole blood
2. LDL-hemoperfusion - A new procedure for LDL-apheresis: Biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients
3. LDL-hemoperfusion using a modified polyacrylate adsorber: In vitro, ex vivo, and first clinical results
4. LDL-hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): Clinical experience from a single center
5. Nonpharmacological lowering of low-density lipoprotein by apheresis and surgical techniques
6. Direct adsorption of LDL and Lp(a) from whole blood: Results of the first clinical long-term study using DALI
7. Direct adsorption of lipoproteins from whole blood by DALI apheresis: Clinical efficacy and biocompatibility
8. DALI - The first human whole-blood LDL and Lp(a) apheresis system in clinical use: Procedure and clinical results
9. DALI apheresis in hyperlipidemic patients: Biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood
10. The determination of kinin and glandular kallikrein in human biological fluids
11. Tissue kallikrein of human seminal plasma is secreted by the prostate gland
12. Prediction of blood volume in normal human adults
13. Lipid apheresis by hemoperfusion: In vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood
14. Low-density lipoprotein apheresis versus lipid lowering drugs in the treatment of severe hypercholesterolemia: Four years' experience
15. LDL-apheresis using the DALI system - State of the art
16. Laboratory and clinical effects of the infusion of ACD solution during platelet pheresis